Efficient hydrolytic cleavage of DNA and antiproliferative effect on human cancer cells by two dinuclear Cu(II) complexes containing a carbohydrazone ligand and 1,10-phenanthroline as a coligand
We report the synthesis, crystal structures and biological activities of two dinuclear Cu(II) complexes [Cu(o-phen)LCu(OAc)] (1) and [Cu(o-phen)LCu(o-phen)](OAc) (2), where o-phen = 1,10-phenanthroline, H3L = o-HOC6H4C(H)=N–NH–C(OH)=N–N=C(H)–C6H4OH-o, and OAc=CH3COO−. Both compounds display strong and broad X-band EPR spectra at RT in their powder state confirming that these are paramagnetic. The intercalative DNA binding of the compounds as revealed from spectrophotometric studies was found to be consistent with the results of fluorescence spectroscopic studies for ethidium bromide displacement assay as well as enhanced viscosity of DNA in the presence of these compounds. The compounds effectively catalyze hydrolytic cleavage of supercoiled pUC19 DNA and show remarkable cytotoxicity toward human lung cancer A549 cell line (IC50 values are 4.34 and 8.46 µM for 1 and 2, respectively) and breast cancer MCF7 cell line (IC50 values are 6.50 and 8.68 µM for 1 and 2, respectively) and are found to be relatively less toxic toward keratinocyte HaCaT normal cell line (IC50 values are 11.19 and 16.01 µM for 1 and 2, respectively). Annexin-V/PI dual staining results analyzed by flow cytometry strongly suggest the induction of apoptotic pathway for the anticancer activity of these complexes. Flow cytometry experiment for cell cycle analysis showed considerable increase in the G2/M phase in both A549 and MCF7 cell lines by these two compounds. On the other hand, compounds 1 and 2 activate reactive oxygen species (ROS) level in A549 cells, but act as scavengers or inhibitors of ROS in MCF7 cell line as analyzed by DCFDA staining using flow cytometry. Two dinuclear Cu(II) complexes exhibit efficient hydrolytic cleavage of DNA and display remarkable cytotoxicity against human lung cancer A549 and breast cancer MCF7cells. The ROS level in A549 cells is activated, but the ROS level in MCF7 cells is decreased in the presence of these complexes. Cell cycle analysis by flow cytometry shows G2/M phase arrest in both these cell lines.
Keywords: Dinuclear Cu(II) complex; EPR and electronic spectra; DNA binding and cleavage; MTT assay; Cytotoxicity and anticancer activity; Cell cycle analysis
Electronic supplementary material The online version of this article (10.1007/s00775-019-01651-8) contains supplementary material, which is available to authorized users.
Introduction
Studies involving DNA binding property, nucleic acid cleavage activity and cell cytotoxicity for the metal complexes, Cu(II) complexes in particular due to their biocompatibility and endogeneity have gained momentum in the past two decades to find new metallodrugs that may serve as anticancer agents [[1]–[22]]. Many copper(II) complexes cleave DNA in the presence of hydrogen peroxide or ascorbic acid [[23]–[28]], but some copper(II) complexes are capable of bringing about hydrolytic cleavage in the absence of any external reagent or light [[29]–[39]] in spite of the great stability of the phosphodiester bond in DNA (k = 3.6 × 10−8 h−1 for unhydrolyzed ds-DNA) [[33], [37]]. Since hydrolytic cleavage involves the hydrolysis of the phosphodiester bond, its great stability is a major concern in hydrolytic cleavage. Therefore, there is a necessity of nucleophilic activation for enormous enhancement of the hydrolysis rate to bring about hydrolytic cleavage. Thus, it is a difficult task to find or synthesize a suitable metallodrug that is capable of cleaving DNA hydrolytically under physiological conditions [[29]–[40]]. We have synthesized two dinuclear Cu(II) compounds capable of efficient hydrolytic cleavage of supercoiled pUC19 DNA and also possess remarkable cytotoxicity toward human lung cancer A549 and breast cancer MCF7 cell lines, but less toxic toward keratinocyte HaCaT normal cell line. Here, we present the synthesis, characterization using ESI–MS, IR, UV–visible, EPR, and X-ray crystal structures and the biological activities of these two closely related dinuclear Cu(II) compounds containing the enol form of the Schiff base ligand 1,5-bis(salicylidene)carbohydrazide, but differing in the types of coligand in the two Cu(II) sites. It is to be noted here that we have reported [[41]] the synthesis and some biological properties such as DNA binding using UV–Vis spectroscopy, cytotoxicity using MTT assay and apoptosis using AO/PI dual staining method for compound 1, along with the corresponding heterodinuclear Zn(II)–Cu(II) compound (3); however, we could not get a single crystal at that time to structurally characterize it. Herein, we confirm its structure by X-ray crystallography along with that of compound 2, and studied the hydrolytic DNA cleavage. Also, to compare the cytotoxicity and cell cycle analysis for 1 and 2 using human A549 and MCF7 cancer cell lines, we have carried out again the MTT assay for 1 along with that of 2, as well as studied their apoptosis using Annexin-V and PI double staining and cell cycle analysis using flow cytometry under identical experimental conditions to obtain the exact differences in the biological properties of these two closely related homodinuclear complexes possessing only one o-phen coligand in the first Cu(II) site and an acetate in the second Cu(II) site of 1 versus two o-phen coligands, one each in both the Cu(II) sites of 2.
Materials and methods
Materials
Carbohydrazide and salicylaldehyde were obtained from Aldrich. Calf thymus DNA was obtained from Sigma. N,N-dimethylformamide (DMF, GR), absolute ethanol, methanol (GR), DMSO, 1,10-phenanthroline monohydrate, and Cu(OAc)2·H2O (GR) were obtained from Merck. Supercoiled (SC) plasmid pUC19 DNA was purchased from Genetix Biotech. All other chemicals were of reagent grades.
Physical measurements
Microanalyses (C, H, N) were performed in a Perkin-Elmer 240C elemental analyzer. Mass spectra were recorded on a PerkinElmer (USA) Flexer SQ 300 MS Mass Spectrometer operating in ESI mode. Infrared spectra were recorded with a Shimadzu IR Affinity-1 FT-IR spectrometer using KBr pellet. Electronic spectra were recorded on a Jasco V-570 UV/VIS/NIR spectrophotometer using a pair of matched quartz cell of path length 1 cm. Electron paramagnetic resonance (EPR) spectra were recorded on a JEOL, Japan Model: JES-FA200 ESR spectrometer with X and Q band. Fluorescence measurements were performed using a Jasco spectrofluorometer model FP-8500.
Syntheses
Preparation of 1,5-bis(salicylidene)carbohydrazide, (o-HOC6H4CH=NNH)2C=O (H3L)
This compound was prepared by the reported method of Koley et al. [[41]]. To a stirring solution of carbohydrazide (5 mmol) dissolved in 30 mL of absolute ethanol, salicylaldehyde (10 mmol) was added dropwise at RT and the reaction mixture was stirred at RT for 2 h while a white compound separated. This was filtered through a G-3 crucible and the pale white solid was washed well with ethanol and air dried. This compound was recrystallized from methanol–ethanol (1:1). Yield 70%; mp 226 °C. Anal. Calc. for C15H14N4O3: C, 60.40; H, 4.73; N, 18.78. Found: C, 60.57; H, 4.76; N, 18.81%.
Preparation of [Cu(o-phen)LCu(OAc)] (1)
This compound was also prepared following the method reported by Koley et al. [[41]]. In brief, a cold (~ 5°C) solution of 1,10-phenanthroline monohydrate (0.2 g, 0.001 mol) and Cu(OAc)2·H2O (0.2 g, 0.001 mol) in methanol (30 mL) was very slowly added to a solution of 1,5-bis(salicylidene)carbohydrazide (0.298 g, 0.001 mol) in 50 mL of methanol during 30 min, while the reaction mixture turned bright green. This was stirred at RT for 3 h, then a solution of Cu(OAc)2·H2O (0.2 g, 0.001 mol) dissolved in methanol (20 mL) was slowly added to this bright green reaction mixture when the solution turned dark green and a dark green compound started separating. This solution was stirred at RT for another 20 h and the dark green compound was filtered through a G-4 crucible, and the mother filtrate was collected. The compound in the crucible was washed well with methanol and air dried, then washed thoroughly with water followed by methanol and dried in vacuo. Yield: 80%. Anal. Calc. for C29H22N6O5Cu2: C, 52.65; H, 3.35; N, 12.70. Found: C, 52.55; H, 3.37; N, 12.71%. ESI–MS in DMSO: m/z 683.82 [M+Na]+ and m/z 701.77 [M+K+H]+.
A part of the mother filtrate was collected in a long tube and left in air for very slow evaporation. Green crystals suitable for X-ray diffraction were obtained within 30 days. We have characterized this compound by X-ray crystal structure (vide infra). These crystals lose their solvent of crystallization (both methanol and water) and become amorphous on long standing at RT or in vacuum.
Preparation of [Cu(o-phen)LCu(o-phen)](OAc) (2)
1,10-Phenanthroline monohydrate (0.398 g, 0.002 mol) in 20 mL of methanol was slowly added to a solution of Cu(OAc)2·H2O (0.398 g, 0.002 mol) dissolved in methanol (20 mL) and the solution was stirred at RT for 30 min and stored at 4 °C. Then this cold blue solution was slowly added to a solution of 1,5-bis(salicylidene)carbohydrazide (0.298 g, 0.001 mol) in 50 mL of methanol during 30 min, while the reaction mixture turned dark green. This was stirred for 20 h at RT and the dark green compound was filtered through a G-4 crucible and the dark green solid was washed very well with methanol and air dried. Then the compound was washed with water and finally washed again with methanol and dried in vacuo. Anal. Calc. for C41H30N8O5Cu2: C, 58.44; H, 3.59; N, 13.30. Found: C, 58.49; H, 3.59; N, 13.37%. ESI–MS in CH3CN: m/z 843.7 [M+2H]+ and m/z 865.5 [M+Na+H]+.
A saturated methanol solution of this green compound was collected in a 5 mL Corning tube that was placed inside a 15 mL Corning tube containing ~ 2 mL toluene and was covered with a cap and left for slow evaporation at RT when blue crystals were obtained within 30 days and were used for X-ray crystallography. It was noted that on long standing (or in vacuum), these crystals also lose their solvent of crystallization and become amorphous.
X-ray crystallography
[Cu(o-phen)LCu(OAc)]2·½CH3OH·½H2O
X-ray data collection was performed with Bruker AXS Kappa Apex III CMOS Diffractometer equipped with graphite monochromated Mo (Kα) (λ = 0.71073 Å) radiation. The automatic cell determination routine, with 24 frames at two different orientations of the detector, was employed to collect reflections for unit cell determination. Further, intensity data for structure determination were collected through an optimized strategy which gave an average fourfold redundancy. The program APEX23-SAINT [[42]] was used for integrating the frames. Fourfold redundancy per reflection was utilized for achieving good multi-scan absorption correction using the program SADABS [[42]]. The structure was solved by SHELXT-2014 [[43]] and refined by full-matrix least-squares techniques using SHELXL-2014, [[43]] computer program. Molecular graphics were drawn using ORTEP3 [[44]]. Hydrogens on all carbon atoms were fixed at calculated positions and refined as riding model with C–H = 0.93 Å, (C–H = 0.96 Å for CH3) Uiso(H) = 1.2Ueq(C) (Uiso(H) = 1.5Ueq(C) for CH3), whereas hydrogens on nitrogen were fixed from the difference electron density peaks and allowed to refine freely. Since methanol and water solvents are disordered, its site occupancy is constrained at 0.5. Also, the positions of hydrogen on these solvents could not be located and refined satisfactorily and hence ignored. The crystal data belong to a non-merohedrally twinned crystal. The twin law [− 1 0 0, 0 − 1 0.466, 0 0 1] was identified by TwinRotMat program and is used for the generation of HKL5 reflection format which was used for refinement. The percentage of twin is given by a batch-scale factor (BASF) of 0.14.
[Cu(o-phen)LCu(o-phen)](OAc)·H2O
X-ray data collection was performed with Bruker AXS Kappa Apex III CMOS dual source diffractometer with Cu (Kα) (λ = 1.54178 Å) radiation. The automatic cell determination routine, with 40 frames at two different orientations of the detector, was employed to collect reflections for unit cell determination. Further, intensity data for structure determination were collected through an optimized strategy which gave an average fourfold redundancy. The program APEX3-SAINT [[42]] was used for integrating the frames. Fourfold redundancy per reflection was utilized for achieving good multi-scan absorption correction using the program SADABS [[42]]. The structure was solved by SHELXT-2014 [[43]] and refined by full-matrix least-squares techniques using SHELXL-2014 [[43]] computer program. Molecular graphics were drawn using ORTEP3 [[44]]. All hydrogens were fixed at calculated positions and refined as riding model with C–H or N–H 0.93 Å, (C–H = 0.96 Å for CH3) Uiso(H) = 1.2Ueq(C) (Uiso(H) = 1.5Ueq(C) for CH3 and N–H). The acetate anion is triply disordered with site occupancies in the ratio of 42:24:34. Hydrogens on disordered solvent molecules could not be located. Crystal data and structure refinement for 1 and 2 are presented in Table 1.
Crystal dataa and structure refinement for 1 and 2
Identification code | Compound 1 | Compound 2 |
---|
Empirical formula | C117 H88 Cu8 N24 O22 | C41 H32 Cu2 N8 O6 |
Formula weight | 2690.43 | 859.82 |
Temperature | 296(2) K | 296(2) K |
Wavelength | 0.71073 Å | 1.54178 Å |
Crystal system | Triclinic | Triclinic |
Space group | P-1 | P-1 |
Unit cell dimensions | a = 12.4593(2) Å | a = 12.0174(7) Å |
| b = 16.0360(2) Å | b = 12.1041(6) Å |
| c = 16.0585(3) Å | c = 14.5463(7) Å |
| α = 76.521(6)° | α = 107.890(3)° |
| β = 89.935(7)° | β = 97.769(4)° |
| γ = 67.478(6)° | γ = 107.645(4)° |
Volume | 2868.20(16) Å3 | 1857.06(18) Å3 |
Z | 1 | 2 |
Density (calculated) | 1.558 mg/m3 | 1.538 mg/m3 |
Absorption coefficient | 1.535 mm−1 | 1.923 mm−1 |
F(000) | 1366 | 880 |
Crystal size | 0.100 × 0.100 × 0.050 mm3 | 0.100 × 0.100 × 0.050 mm3 |
Theta range for data collection | 2.678°–21.910° | 3.299°–66.992° |
Index ranges | − 12 ≤ h ≤ 12, − 16 ≤ k ≤ 16, − 16 ≤ l ≤ 16 | − 13 ≤ h ≤ 14, − 14 ≤ k ≤ 14, − 17 ≤ l ≤ 17 |
Reflections collected | 33,612 | 48,548 |
Independent reflections | 33,612 [R(int) = ?] | 6616 [R(int) = 0.2148] |
Completeness to theta | (= 21.910°) 98.5% | (= 66.992°) 99.9% |
Absorption correction | Semi-empirical from equivalents | Semi-empirical from equivalents |
Max. and min. transmission | 0.7457 and 0.5487 | 0.75 and 0.63 |
Refinement method | Full-matrix least-squares on F2 | Full-matrix least-squares on F2 |
Data/restraints/parameters | 33,612/64/789 | 6616/250/600 |
Goodness-of-fit on F2 | 1.047 | 1.022 |
Final R indices [I > 2sigma(I)] | R1 = 0.0823, wR2 = 0.2295 | R1 = 0.0785, wR2 = 0.1802 |
R indices (all data) | R1 = 0.1249, wR2 = 0.2627 | R1 = 0.1550, wR2 = 0.2245 |
Extinction coefficient | n/a | 0.0004(2) |
Largest diff. peak and hole | 1.478 and − 0.816 e Å−3 | 0.623 and − 0.531 e Å−3 |
aCrystallographic data for the structural analysis have been deposited with the Cambridge Crystallographic Data Center; numbers are CCDC 1887320 for compound 1 and CCDC 1887321 for compound 2, respectively
DNA binding experiments
Absorption spectral studies
Absorption titrations were performed by adding incremental amounts of calf thymus DNA (CT-DNA) to a complex solution having concentration of 5 × 10−5 M in 10 mM Tris–HCl buffer at pH 7.4. The concentration of CT-DNA was calculated from the absorbance at 260 nm with the molar extinction coefficient for CT-DNA as 6600 M−1 cm−1 at 260 nm. After every incremental addition of DNA, the reaction mixture was allowed to equilibrate for 2 min at room temperature after which the absorption spectra was recorded. The experimental data were used to calculate the intrinsic binding constant Kb.
Viscosity measurements
Viscosity measurements were carried using CT-DNA (100 µM) with increasing concentrations (0–100 µM) of the complexes 1 and 2 using Ostwald viscometer. Viscosity values were calculated from the flow time of buffer alone (t0) and flow time of each sample (t) using the equation η = (t − t0)/t0. Data were presented by plotting values of relative viscosity (η/η0)1/3 against [complex]/[DNA], where η is the viscosity of DNA in the presence of complex and η0 is the viscosity of DNA alone.
Competitive DNA binding fluorescence measurements
The competitive binding studies using ethidium bromide (EB)-bound CT-DNA was investigated using fluorescent spectrometry. The experiments were carried out by adding incremental amounts of complexes 1 and 2 into EB–DNA solution (2 µM EB and 50 µM CT-DNA) in 10 mM Tris HCl buffer (pH 7.9). The solutions were incubated at room temperature for 5 min to fully react, prior to recording the spectra. The effect of addition of increasing amounts of 1 and 2 to the EB–DNA complex was monitored by recording the variation of fluorescence emission spectra with excitation at 510 nm and emission at 597 nm. The behavior was analyzed through the Stern–Volmer equation and the apparent binding constant (Kapp) was calculated.
DNA cleavage experiments
The interaction of the complexes 1 and 2 with supercoiled pUC19 DNA was studied using agarose gel electrophoresis. The cleavage of pUC19 DNA was accomplished by treating SC plasmid pUC19 DNA (200 ng) with different concentrations of complexes 1 and 2 in 50 mM Tris–HCl buffer (pH 8.0), the samples were incubated for 3 h at 37 °C in dark, after which a loading buffer containing 25% bromophenol blue, 0.25% xylene cyanol and 30% glycerol was added, electrophoresis was performed at 60 V for 1.5 h and analyzed for cleaved products. The gel was stained with 0.5 µg/mL ethidium bromide and viewed under UV light. The bands originating from SC (form I) and NC (form II) in hydrolytic DNA cleavage experiments were quantified using image J. The ability of the complexes to convert the supercoiled (SC, form I) to nicked circular (NC, form II) DNA was used to measure the cleavage efficiency.
Oxidative DNA cleavage by the complexes was studied by performing reactions in dark using hydrogen peroxide (0.1 mM) as the oxidizing agent in the absence and presence of the complex (0–25 µM). The solutions were incubated at 37 °C for 1 h, subjected to electrophoresis and analyzed for DNA cleaved products. For mechanistic investigations, experiments were also conducted in the presence of radical scavengers such as DMSO (2 µL), a hydroxyl radical scavenger, and NaN3 (100 µM), a singlet oxygen quencher, which were added to pUC19 DNA prior to the addition of complex.
To ensure that the copper complexes 1 and 2 as a whole are responsible for cleavage of DNA, control experiments were performed with Cu(OAc)2·H2O (500 µM), free ligands 1,5-bis(salicylidene)carbohydrazide (500 µM) and 1,10-phenanthroline monohydrate (500 µM).
For kinetic measurements, the DNA cleavage rate was measured keeping fixed concentrations of DNA (200 ng) and 1 or 2 (200 µM) at 37 °C for different time intervals. The decrease in form I was plotted against time and the data fitted into a single exponential decay curve; thereafter, the hydrolysis rate constant Kobs was calculated to determine the rate enhancement in comparison to that of unhydrolyzed rate of ds-DNA.
Cell culture and treatment
Cancer cell lines A549, MCF7 and normal human keratinocyte HaCaT cells were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). HaCaT and MCF7 cell lines were cultured in DMEM, while A549 cell line was cultured in DMEM F12, supplemented with 10% FBS and antibiotic–antimycotic at 37 °C with 5% CO2 in a CO2 incubator. The cells were subcultured after they had reached 70–80% confluence by trypsinization and used for further experimental purpose.
Cell viability assay
Cell viability was assessed by MTT assay according to a previously standardized protocol [[45]]. Briefly, A549, MCF7 and HaCaT cells (5 × 103 cells/well) were seeded in 96-well plates and treated with 1, 2.5, 5, 10, 15 and 20 µM of compounds 1 and 2 for 24 h. After completion of treatment, cells were incubated with 500 µg/mL MTT (3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium) at 37 °C for 2 h. Culture media were removed and the formazan crystals were dissolved in 100 µL of DMSO. The color intensity was measured in a BMG fluostar Optima plate reader at 450 nm and percentage cell viability was calculated. The cytotoxicity of the free Schiff base ligand and the free coligand 1,10-phenanthroline were also studied using the human lung cancer A549 cell line with different concentrations (0.5 µM, 1.0 µM, 2.5 µM, 5 µM and 10 µM) of these free ligands.
Quantification of apoptosis by Annexin-V and PI double staining
A549 and MCF7 cells were cultured in DMEM media and treated with different concentrations (1, 2.5, 5, 10, 15 and 20 µM) of compounds 1 and 2 for 24 h. Apoptosis was measured by flow cytometry using Annexin-V/PI labeling according to the previously described protocol [[45]]. Briefly, A549 and MCF7 cells were incubated in 100 µL staining solution (5 µL PI and 3 µL Annexin-V FITC in the 1× binding buffer) for 15 min at room temperature. The volume was made up to 300 µL by 1× binding buffer and apoptosis was measured using flow cytometry FACS caliber and data were analyzed with Modfit software.
Cell cycle analysis
The different phases of cell cycle were analyzed by flow cytometry as in a previously described protocol [[45]]. A549 and MCF7 cells were cultured in DMEM media and treated with 1 µM, 2.5 µM, 5 µM and 10 µM concentration of compounds 1 and 2 for 24 h. In brief, cells were fixed in 70% ice cold ethanol for 1 h on ice and washed with 1× PBS twice. Fixed cells were incubated in 300 µL staining solution (50 µg/mL propidium iodide and 50 µg/mL RNaseA in 1× PBS for 30 min at room temperature in dark). Specific cell cycle phase arrest was assessed by FACS caliber and data were analyzed with Modfit software.
Reactive oxygen species (ROS) detection assay
The generation of reactive oxygen species (ROS) in A549 and MCF7 cells was detected using ROS-sensitive fluorescent probe 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA). In cells, H2DCFDA is hydrolyzed by esterases into H2DCF and further oxidized by ROS to 2′,7′-dichlorodihydrofluorescein (DCF) which exhibits intense green fluorescence. Briefly, the cultured cells were treated with different concentrations (1, 2.5, 5 and 10 µM) of compounds 1 and 2 for 24 h, untreated cells were maintained as control and cells treated with freshly prepared H2O2 were used as positive control. After completion of treatment, cells were trypsinized and washed with 1× PBS. Subsequently, the samples were incubated in 10 µM DCFDA for 30 min at room temperature in dark. Cellular reactive oxygen species (ROS) generation was measured by flow cytometry by DCFDA staining at 488 nm excitation and 535 emission laser.
Statistical analysis
All assays with established cell lines were repeated three times. Data are expressed as the mean ± standard deviation and analyzed by one-way analysis with differences considered significant at *< 0.05, **< 0.01, and ***< 0.001 (GraphPad Prism 5).
Results and discussion
Synthesis and characterization
The free Schiff base ligand 1,5-bis(salicylidene)carbohydrazide (A) which is in keto form in the solid [[41]] can be in its enol form in solution that can exist either in syn (B) or anti (B′) as shown in Scheme 1. B′ possesses two distinctly different tridentate coordination sites: the first site is characterized by one phenolate O−, one enolate O− and one imine N, and the second site is characterized by other phenolate O−, other imine N and the secondary NH donor atom. Coordination of the ligand in its B′ form in both 1 and 2 is confirmed from the crystal structures of both the compounds (vide infra).
Graph: Scheme 1Proposed structures of the ligand in its keto and enol forms
The reaction of Cu(OAc)2·H2O with 1,5-bis(salicylidene)carbohydrazide (A) in methanol in the presence of 1,10-phenanthroline (o-phen) in the ratio of 2:1:1 resulted in the dinuclear Cu(II) complex containing one coordinated o-phen coligand to the first Cu(II) center and one acetate coordinated to the second Cu(II) center in compound 1, and the reaction in the ratio of 2:1:2 yielded compound 2, both the Cu(II) centers containing one o-phen each and one acetate counteranion.
The solubility of the complexes is low in methanol and acetonitrile, but they are readily soluble in DMF and DMSO. The ESI-MS spectra for complexes 1–2 have been recorded in the positive-ion mode and the results are presented in Fig. S1 (Supplementary material). Complex 1 showed peaks at m/z 683.82 [M+Na]+ and m/z 701.77 [M+K+H]+, while compound 2 showed peaks at m/z 843.7 [M+2H]+ and m/z 865.5 [M+Na+H]+, respectively. Both the compounds display strong X-band EPR at RT in their powder state (Fig. S2, Supplementary material) with g values of 2.09 for 1 and 2.10 for 2, suggesting they are paramagnetic. Also, the presence of forbidden ΔMs = ± 2 line around g ~ 4 in both of them (Fig. S2, inset) clearly suggests that it results from a dimer Cu–Cu interaction. Based on their physico-chemical properties, elemental analysis, mass spectra and X-band EPR results, the proposed structures of 1–2 are shown in Scheme 2.
Graph: Scheme 2Proposed structures of the compounds 1–2
The IR spectrum of the powder sample of the free ligand 1,5-bis(salicylidene)carbohydrazide (A) clearly shows the ν(C=O) at 1690 cm−1 and ν(C=N) at 1625 cm−1 (figure not shown), respectively, suggesting it exists in its keto form which was confirmed previously from its crystal structure [[41]]. The ν(C=O) band at 1690 cm−1 is found to be absent in the IR spectra of both 1 and 2, and the band at 1625 cm−1 due to ν(C=N) of the free ligand is shifted to 1605 cm−1 in the IR spectra of both the complexes indicating the coordination of the imine N to the metal ion. This is confirmed from the crystal structures of 1 and 2.
The electronic absorption spectra of both the compounds in DMSO are found to be very similar (Fig. S3, Supplementary material) suggesting their very similar electronic structures. Both the compounds display ligand field transitions around 622 nm, followed by strong LMCT in the visible region apart from other charge transfer transitions in the UV region.
Crystal structures of [Cu(o-phen)LCu(OAc)]2·½CH3OH·½H2O and [Cu(o-phen)LCu(o-phen)] (OAc)·H2O
The structures of the compounds 1 and 2 have been determined by X-ray crystallography. Figure 1 shows the ORTEP representation of the molecule of 1 with 40% probability ellipsoids [[44]]. The crystal for 1 is indexed in triclinic system with space group P-1 and lattice parameters a = 12.4593(2) Å, b = 16.0360(2) Å, c = 16.0585(3) Å, α = 76.521(6)°, β = 89.935(7)°, γ = 67.478(6)°.
Graph: Fig. 1ORTEP diagram of the compound [Cu(o -phen)LCu(OAc)] 2 ·½CH 3 OH·½H 2 O. Selected bond lengths (Å) and angles (°):N(1)–Cu(2), 1.918(10); N(2)–Cu(1), 1.978(11); N(4)–Cu(1), 1.964(10); N(5)–Cu(2), 2.266(12); N(6)–Cu(2), 1.985(11); N(7)–Cu(4), 1.944(11); N(8)–Cu(3), 1.999(11); N(10)–Cu(3), 1.958(11); N(11)–Cu(4), 1.996(11); N(12)–Cu(4), 2.264(11); O(1)–Cu(2), 1.899(9); O(2)–Cu(2), 2.013(9); O(3)–Cu(1), 1.880(10); O(4)–Cu(1), 1.956(9); O(6)–Cu(4), 1.895(10); O(7)–Cu(4), 2.018(9); O(8)–Cu(3), 1.883(10); O(9)–Cu(3), 1.958(9); O(3)–Cu(1)–O(4), 93.5(4); O(3)–Cu(1)–N(4), 90.9(4); O(4)–Cu(1)–N(4), 169.8(4); O(3)–Cu(1)–N(2), 166.0(5); O(4)–Cu(1)–N(2), 96.7(4); N(4)–Cu(1)–N(2), 80.7(4); O(1)–Cu(2)–N(1), 94.5(4); O(1)–Cu(2)–N(6), 95.3(4); N(1)–Cu(2)–N(6), 169.7(4); O(1)–Cu(2)–O(2), 163.1(4); N(1)–Cu(2)–O(2), 81.5(4); N(6)–Cu(2)–O(2), 88.2(4); O(1)–Cu(2)–N(5), 110.5(4); N(1)–Cu(2)–N(5), 99.3(4); N(6)–Cu(2)–N(5), 80.0(4); O(2)–Cu(2)–N(5), 86.3(4); O(8)–Cu(3)–N(10), 91.2(5); O(8)–Cu(3)–O(9), 93.2(4); N(10)–Cu(3)–O(9), 170.4(4); O(8)–Cu(3)–N(8), 165.5(5); N(10)–Cu(3)–N(8), 80.1(4); O(9)–Cu(3)–N(8), 97.2(4); O(6)–Cu(4)–N(7), 94.5(5); O(6)–Cu(4)–N(11), 95.5(4); N(7)–Cu(4)–N(11), 169.7(5); O(6)–Cu(4)–O(7), 162.7(4); N(7)–Cu(4)–O(7), 81.1(4); N(11)–Cu(4)–O(7), 88.6(4); O(6)–Cu(4)–N(12), 111.4(4); N(7)–Cu(4)–N(12), 99.5(4); N(11)–Cu(4)–N(12), 79.2(4); O(7)–Cu(4)–N(12), 85.9(4)
The asymmetric unit of the crystal contains two crystallographically independent molecules of binuclear copper complex, half molecule of methanol and half molecule of water. The central copper atom shows penta-coordination forming distorted square pyramidal geometry. The unique hexadentate ligand connects two copper atoms with a Cu–Cu distance of 4.75 Å. The acetate anion is co-ordinated to Cu1 and Cu3 through its bidentate binding mode and the 1,10-phenanthroline moiety is co-ordinated to Cu2 and Cu4. The two binuclear copper complexes in the asymmetric unit are held (Fig. 2) together by N(3)-H(3A)...O(10) hydrogen bond interaction with a d(H...A) distance of 1.94(5) Å. In addition to this, the crystal lattice is stabilized by CH...O and CH...π interactions and also by the solvent-mediated hydrogen bond interactions. The overall structure of this compound is found to be similar to that of the compound Zn(o-phen)LCu(OAc)·0.5H2O·0.5CH3OH we have reported earlier [[41]].
Graph: Fig. 2Packing of the molecules of 1 in the unit cell
Figure 3 shows the ORTEP representation of compound 2 with 40% probability ellipsoids [[42]]. The molecule of 2 crystallizes in triclinic crystal system with space group P-1. The lattice parameters are: a = 12.0174(7) Å, b = 12.1041(6) Å, c = 14.5463(7) Å, α = 107.890(3)°, β = 97.769(4)°, γ = 107.645(4)°. The asymmetric unit of the crystal contains one binuclear copper complex, one molecule of acetate anion and one molecule of water. The copper atoms show penta-coordination forming distorted square pyramidal geometry. The unique hexadentate ligand connects two copper atoms with a Cu–Cu distance of 4.73 Å. The disordered acetate anion does not show any coordination to metal atoms; instead, it participates in H-bond interaction with the N–H moiety of the hexadentate ligand. Solvent-mediated H-bond interactions hold the binuclear copper complexes together in the crystal lattice (Fig. 4).
Graph: Fig. 3ORTEP diagram of the compound [Cu(o -phen)LCu(o -phen)] (OAc)·H 2 O. Selected bond lengths (Å) and angles (°):N(1)–Cu(1), 1.948(6); N(3)–Cu(2), 1.936(6); N(4)–Cu(2), 2.024(6); N(5)–Cu(2), 2.306(6); N(6)–Cu(1), 2.021(6); N(7)–Cu(1), 2.326(7); N(8)–Cu(1), 2.005(6); O(1)–Cu(1), 1.901(5); O(2)–Cu(2), 1.959(5); O(3)–Cu(2), 1.902(5); O(1)–Cu(1)–N(8), 162.4(3); N(1)–Cu(1)–N(8), 79.8(2); O(1)–Cu(1)–N(6), 90.0(2); N(1)–Cu(1)–N(6), 174.2(3); N(8)–Cu(1)–N(6), 99.8(2); O(1)–Cu(1)–N(7), 103.1(2); N(1)–Cu(1)–N(7), 97.2(2); N(8)–Cu(1)–N(7), 93.4(2); N(6)–Cu(1)–N(7), 77.0(2); O(3)–Cu(2)–N(3), 93.7(2); O(3)–Cu(2)–O(2), 163.3(2); N(3)–Cu(2)–O(2), 81.4(2); O(3)–Cu(2)–N(4), 92.0(2); N(3)–Cu(2)–N(4), 174.3(2); O(2)–Cu(2)–N(4), 93.0(2); O(3)–Cu(2)–N(5), 95.3(2); N(3)–Cu(2)–N(5), 103.1(2); O(2)–Cu(2)–N(5), 101.3(2); N(4)–Cu(2)–N(5), 76.8(2)
Graph: Fig. 4Packing of the molecules of 2 in the unit cell
DNA binding studies
Absorption spectroscopic studies
The binding affinity of complex 2 toward calf thymus DNA (CT-DNA) has been studied by electronic absorption spectroscopy. In general, the absorption spectra of metal complexes binding to CT-DNA through intercalative mode show decrease in molar absorptivity due to strong stacking interaction between the aromatic chromophore of the ligand and the DNA base pairs. The UV–Vis absorption spectrum of compound 2 is significantly perturbed on addition of incremental amounts of CT-DNA (Fig. 5). The absorption band at 396 nm shows hypochromism of 67.3% for 2. The observed spectroscopic changes thus imply intercalation of 2 into the DNA base stack. A similar result was observed for 1 as we have reported earlier [[41]]. The intrinsic binding constant (Kb) for the association of 2 with CT-DNA was determined quantitatively using the Eq. (1):
Graph
where [DNA] denotes the concentration of CT-DNA, and the apparent extinction coefficient (εa) was obtained by calculating Abs/[complex]. The terms εf and εb denote the extinction coefficients of free (unbound) and the fully bound complexes, respectively. The binding constant was calculated from the ratio of the slope to the intercept of the plot of [DNA]/(εa − εf) versus [DNA]. The observed Kb value was found to be 2.86 × 105 M−1 for 2 which is slightly higher than that reported (2.63 × 105 M−1) for 1 [[41]], suggesting that complex 2 has a higher DNA binding affinity than 1.
Graph: Fig. 5Change in electronic absorption spectra of 2 [5 × 10 −5 M] upon titration with CT-DNA (0–30 µM) dissolved in 10 mM Tris–HCl buffer (pH 7.4). The figure in inset shows the linear fit of [DNA]/(εa − εf) versus [DNA]. Intrinsic binding constant Kb = 2.86 × 10 5 M −1 (R2 = 0.99874 for 11 points)
Viscosity measurements
As a means to further support the intercalative mode of DNA binding results obtained from spectroscopic analysis, viscosity measurements were carried out to study the effect of increasing concentrations of both 1 and 2 on CT-DNA. A classical intercalative mode of binding causes significant increase in viscosity, because insertion of intercalator causes the base pairs of DNA to separate and unwind resulting in an increase in the overall length of DNA, which increases the viscosity. Based on our observations, the data plotted for the relative viscosity (η/η0)1/3 against [complex]/[DNA] (Fig. 6) reveal that there is steady increase in viscosity in case of both copper complexes 1 and 2 which confirms the intercalative mode of binding of the copper(II) complexes to CT-DNA. It is to be noted that increase in viscosity is more prominent in 2 than 1 which is found to be in line with spectral studies.
Graph: Fig. 6Effect of increasing amount of 1 and 2 on the relative viscosity of CT-DNA (100 µM) in 10 mM Tris–HCl buffer (pH 7.4) at room temperature
Competitive DNA binding: fluorescence studies
Ethidium bromide (EB) is a planar intercalating dye which emits fluorescence upon binding to calf thymus DNA. We performed ethidium bromide displacement assay to examine the ability of the complexes 1 and 2 to replace EB from the EB–DNA complex. The interaction of complexes 1 and 2 with ethidium bromide-bound CT-DNA in 10 mM Tris–HCl buffer (pH 7.9) was carried out and it was found that the emission band at 597 nm of the EB–DNA system decreased in intensity with increase in complex concentration (Fig. 7). This observation implies that both the complexes have been able to displace EB from EB–DNA complex and such characteristic decrease is observed in DNA interaction by the intercalative mode. The quenching of EB bound to DNA by the copper complexes 1 and 2 is in agreement with the linear Stern–Volmer equation (2) (Fig. 7 inset):
2
Graph
where F0 and F are the emission intensities of EB-bound CT-DNA in the absence and presence of the quencher (complex) concentration [Q], respectively, and is the KSV Stern–Volmer quenching constant. The plot of F/F0 vs. complex concentration at 597 nm was used to calculate the apparent binding constant from 50% quenching using Eq. (3):
3
Graph
where [complex]50 is the complex concentration at 50% reduction of the fluorescence intensity of EB-bound CT-DNA, KEB is the binding constant of EB (KEB = 1.0 × 107 M−1) and [EB] is the concentration of ethidium bromide used (2 µM). The calculated apparent binding constant (Kapp) for the complexes are 1.02 × 106 M−1 for complex 1 and 1.43 × 106 M−1 for 2, thus it is observed that Kapp of 2 > 1, which shows a similar trend to the Kb values obtained from UV–Vis absorption spectral studies. It is also to be noted that the Kapp of the complexes 1 and 2 are observed to be tenfold lower than the binding constant of classical intercalator EB (1 × 107 M−1).
Graph: Fig. 7Effect of the addition of complexes 1 (a) and 2 (b) on the emission intensity of ethidium bromide-bound CT-DNA at different concentrations in 10 mM Tris–HCl buffer (pH 7.9). λex = 510 nm. The arrow shows the change in fluorescence intensity with increasing complex concentration. The inset shows the linear fit of F0 / F versus [complex]
Cleavage activity with pUC19 DNA
The ability of the complexes 1 and 2 to cleave DNA was assessed by performing gel electrophoresis on supercoiled plasmid DNA pUC19 as the substrate in a medium of 50 mM Tris–HCl buffer (pH 8.0) in the absence of any external additives or light. Both complexes were found to cleave DNA hydrolytically. The distribution of the supercoiled (SC) and nicked forms (NC) in the agarose gel electrophoresis was used to measure the extent of hydrolysis of the phosphodiester bond. At a complex concentration of 30 µM and an incubation time of 3 h, 1 cleaves 19% of SC DNA (Fig. 8a, lane 5), while 90% cleavage is observed for 2 (Fig. 8c, lane 5). Again at 50 µM concentration, 1 cleaves 87% of SC DNA (Fig. 8b, lane 2), while complete cleavage is observed for 2 (Fig. 8d, lane 2). This greater nuclease activity of 2 as compared to 1 can be possibly rationalized on the basis of its higher binding affinity toward CT-DNA as reflected from DNA binding studies.
Graph: Fig. 8Hydrolytic and oxidative cleavage of supercoiled pUC19 DNA (200 ng) at 37 °C in 50 mM Tris–HCl buffer (pH 8.0). a Lane 1, DNA control; lane 2, DNA + 1 (5 µM); lane 3, DNA + 1 (10 µM); lane 4, DNA + 1 (20 µM); lane 5, DNA + 1 (30 µM); lane 6, DNA + 1 (40 µM); lane 7, DNA + 1 (50 µM). b Lane 1, DNA control; lane 2, DNA + 1 (50 µM); lane 3, DNA + 1 (100 µM); lane 4, DNA + 1 (150 µM); lane 5, DNA + 1 (200 µM). c Lane 1, DNA control; lane 2, DNA + 2 (5 µM); lane 3, DNA + 2 (10 µM); lane 4, DNA + 2 (20 µM); lane 5, DNA + 2 (30 µM). d Lane 1, DNA control; lane 2, DNA + 2 (50 µM); lane 3, DNA + 2 (100 µM); lane 4, DNA + 2 (150 µM); lane 5, DNA + 2 (200 µM). e Lane 1, DNA + H 2 O 2 control; lane 2, DNA + 2 (5 µM) + H 2 O 2 ; lane 3, DNA + 2 (15 µM) + H 2 O 2 ; lane 4, DNA + 2 (25 µM) + H 2 O 2 ; lane 5, DNA + 2 (25 µM) + H 2 O 2 + DMSO (2 µL); lane 6, DNA + 2 (25 µM) + H 2 O 2 + NaN 3 (100 µM). f Lane 1, control DNA; lane 2, DNA + Cu(OAc) 2 ·2H 2 O (500 µM); lane 3, DNA + 1,5-bis(salicylidene)carbohydrazide (500 µM); lane 4, DNA + 1,10-phenanthroline monohydrate (500 µM)
The nuclease activity of the complexes has also been studied in the presence of H2O2. A figure representing oxidative DNA cleavage by complex 2 has been incorporated (Fig. 8e, lanes 1–4), which shows that with increasing concentration (0–25 μM) of complex 2, supercoiled DNA is gradually converted completely to the nicked form. To elucidate the mechanistic aspects of the chemical-induced DNA cleavage, experiments were conducted in the presence of inhibitors. Oxidative DNA cleavage performed in the presence of DMSO, a known scavenger of hydroxyl ion, showed considerable inhibition of cleavage (Fig. 8e, lane 5); on the other hand, the presence of NaN3, a singlet oxygen quencher, did not have any considerable effect on the DNA cleaving ability of the complex (Fig. 8e, lane 6). Thus, it may be concluded that hydroxyl ion is associated with DNA cleavage exhibited by the complexes.
To ensure that the copper complexes 1 and 2 as a whole are responsible for cleavage of DNA, control experiments were performed with Cu(OAc)2·H2O (500 µM), free ligands 1,5-bis(salicylidene)carbohydrazide, (500 µM) and 1,10-phenanthroline monohydrate (500 µM). No cleavage was observed with either Cu(OAc)2·H2O, ligand 1,5-bis(salicylidene)carbohydrazide or coligand 1,10-phenanthroline monohydrate (Fig. 8f, lanes 2–4), even at a concentration of 500 µM. This confirms that neither Cu(OAc)2·H2O nor the free ligands alone are capable of bringing about DNA strand cleavage.
Further, the kinetics of DNA cleavage were studied by monitoring the % DNA cleavage by the complexes 1 and 2 (200 µM) with time (Fig. 9). The time-dependent decrease of form I and increase of form II were found to fit well to a single-exponential decay and increase, respectively. A plot of log (% SC DNA) with time gave a linear fit from which the hydrolytic rate constant (kobs) was obtained. The kobs value obtained were 11.55 h−1 for 1 and 11.63 h−1 for 2, respectively. This amounts to an enormous enhancement of cleavage rate of 3.21–3.23 × 108 in comparison to the unhydrolyzed rate of ds-DNA (k = 3.6 × 10−8 h−1). This rate enhancement is much higher than the rate enhancements reported for most of the transition metal-based synthetic hydrolases [[29], [36], [45]].
Graph: Fig. 9Hydrolytic cleavage of SC pUC19 DNA (200 ng) showing the decrease in form I (SC DNA) and the formation of form II (NC DNA) with the incubation time (in dark at 37 °C): a using 200 µM concentration of 1; inset shows the plot of log(% SC DNA) vs. time for complex 1 (200 µM). b Using 200 µM concentration of 2; inset shows the plot of log (% SC DNA) vs. time for complex 2 (200 µM)
Cytotoxicity
Cell proliferation
The cytotoxicity of the complexes was tested against cells from A549 lung cancer cell line, MCF7 breast cancer cell line and HaCaT human keratinocyte normal cell line using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. From the percentage cell viability versus complex concentration plot (Fig. 10), a dose-dependent cell death-inducing ability was observed for both the complexes 1 and 2. It is observed that complex 1 exhibits more cytotoxicity than 2 in both A549 and MCF7cell lines. Most importantly, the complexes 1 and 2 appear to be comparatively less toxic to normal HaCaT cells (Fig. 10e, f). Especially in case of complex 2, not much toxicity is observed till 5 µM dose in HaCaT cell line. At 10 µM concentration, 2 exhibited significant cytotoxicity as seen from cell viability of ~ 48% in both cancerous cell lines A549 and MCF7, whereas the cell viability was ~ 90% in normal HaCaT cell line; this marked difference between the cytotoxic effect in cancerous and noncancerous cell lines is of considerable importance. The IC50 values are presented in Table 2. The IC50 values for 1 and 2 for both A549 and MCF7 cell lines are found to be higher than that reported for cisplatin (4.13 µM for A549, 3.92 µM for MCF7). However, the IC50 values for 1 and 2 for MCF7 cell line are found to be much lower than that reported for carboplatin (36.65 µM for MCF7) [[34]]. Another point to be noted that though the results of DNA binding and cleavage studies exhibited by compounds 1 and 2 are very similar, their cytotoxic behavior toward A549, MCF7 and HaCaT cell lines are considerably different. This difference may originate from the difference in their abilities to diffuse across the cell membrane. Compound 1 being uncharged polar molecule will be able to passively diffuse across the cell membrane. On the other hand, compound 2 being ionic will find it difficult to diffuse across the cell membrane as compared to compound 1 [[47]]. Another point to be mentioned here is that the reported [[41]] neutral heterodinuclear Zn(II)/Cu(II) compound [Zn(o-phen)LCu(OAc)] (3) containing the enol form of the same carbohydrazone Schiff base (H3L = o-HOC6H4C(H)=N–NH–C(OH)=N–N=C(H)-C6H4OH-o), which is structurally very similar to compound 1 under study, also exhibited [[41]] very high cytotoxicity against the human lung cancer A549 cell line (IC50 = 4.80 μM) and for the breast cancer MCF7 cell line (IC50 = 3.6 μM). At the same time, both these compounds 1 and 3 were found to be much less toxic at their 10 μM concentrations toward HaCaT normal cell line. On the other hand, compound 2, which also contains Cu(II) in both the sites like compound 1, but containing o-phen coligands in both the Cu(II) centers, exhibits relatively lesser cytotoxicity, in spite of containing two o-phen coligands in the molecule, not only toward both the cancer cells but also toward HaCaT normal cells as compared to compound 1 containing only one o-phen coligand in the first Cu(II) site and acetate in the second Cu(II) site.
Graph: Fig. 10Effect of 1 and 2 on cell viability in A549, MCF7 and HaCaT cell lines. Cells were treated with compounds 1 and 2 for 24 h. Effect of 1 and 2 on cell viability in a, b A549, c, d MCF7 and e, f HaCaT was analyzed by MTT assay. Data of three independent experiments are presented as mean ± SD. Difference in significance was determined by one-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001, ns not significant
IC50 values for the compounds 1 and 2 calculated from the plot of cell viability versus concentration in the MTT assay
Cell line | IC50 (µM) |
---|
Compd 1 | Compd 2 |
---|
A549 | 4.34 | 8.46 |
MCF 7 | 6.50 | 8.68 |
HaCaT | 11.19 | 16.01 |
We have also studied the cytotoxicity of the free ligands to compare that with their metal bound states in compounds 1 and 2. The cytotoxicity study of the free Schiff base ligand and the free coligand 1,10-phenanthroline were carried out using the human lung cancer A549 cell line as a model case with different concentrations (0.5 µM, 1.0 µM, 2.5 µM, 5 µM, and 10 µM) of these free ligands for 24 h. The cell viabilities were found to be nearly 87% and 72% with 10 µM of the free Schiff base ligand and the free 1,10-phenanthroline ligand, respectively (Fig. S4, Supplementary material), suggesting that the free ligands are capable of causing individually about 13% and 28% cell death at 10 µM concentrations. On the other hand, the cell viabilities for the compounds 1 and 2 were found to be nearly 21% and 48% with 10 µM concentrations of 1 and 2, respectively. Thus, copper chelation with these ligands certainly increased their toxicity, as observed for many other cases [[1]].
Very recently, we have reported [[48]] the cytotoxicity of a five-coordinate Cu(II) compound [Cu(pabt)(o-phen)](ClO4) (4), (Hpabt = N-(2-mercaptophenyl)-2′-pyridylmethylenimine, o-phen = 1,10-phenanthroline) with A549 cell line and the IC50 value was found to be 5.26 μM, suggesting it is highly potent for the A549 cells. This compound was found to be much less toxic toward the human keratinocyte HaCaT normal cells. Also, we have recently reported [[49]] the cytotoxicity of another five-coordinate [CuL(o-phen)] (5) and a four-coordinate [CuL(Imz)] (6), (H2L = o-HOC6H4C(H)=NC6H4OH-o, o-phen = 1,10-phenanthroline, and Imz = imidazole) compounds with A549 and MCF7 cancer cell lines. Both these complexes were found to be very toxic for A549 cells (IC50 values were 0.67 and 0.59 μM, respectively) as well as quite toxic for MCF7 cells (IC50 values were 6.30 and 8.88 μM, respectively), but these two compounds were found to be equally toxic for HaCaT normal cells. Lu et al. [[34]] have studied the cytotoxicity of Cu(II) complexes, which also exhibited lower IC50 values in A549 as well as MCF7 cell lines, but the cytotoxic effect of these compounds on any normal cell line was not reported. Anjomshoa et al. [[50]] have studied the anticancer activity of a mononuclear Cu(II) complex with 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine ligand and the reported IC50 values were 7.80 and 9.80 μM for A549 and MCF7 cells, respectively. Nair and coworkers [[13]] have studied the cytotoxic effects of two copper(II) complexes of terpyridine derivatives with human breast cancer MCF7 cell line and the IC50 values were found to be 6.25 and 3.125 μM for those two complexes. Abdi et al. [[51]] have reported the IC50 value for MCF7 cells (4.57 μM) of a mononuclear copper(II) complex with terpyridine and an extended phenanthroline base. Meenongwa et al. [[52]] have studied the effects of N,N-heterocyclic ligands on the in vitro cytotoxicity of some copper(II) chloride complexes with MCF7 cells, and a few of these compounds were found to be cytotoxic toward this cell line. Inspired by the first synthetic chemical nuclease, [Cu(phen)2]2+ (phen = 1,10-phenanthroline), and based on the results that mononuclear [Cu(phen)2(phthalate)] complexes exhibited very good chemotherapeutic potential against colon (HT29), breast (MCF7) and prostate (DU145) cancer cell lines, Kellett et al. [[53]] have synthesized and studied the water-soluble bis(1,10-phenanthroline) octanedioate Cu2+ (and Mn2+) complexes that displayed extremely high cytotoxicity toward some human cancer cell lines (HT29, SW480 and SW620), but these were found to be less toxic toward normal human keratinocyte cells (HaCaT).
Copper(II) complexes with terpyridine ligands studied by Djuran and coworkers [[54]] exhibited very low IC50 values for A549 cells (1.2–1.9 μM). Apart from these there are studies [[55]–[57]] by Nair and coworkers involving A549 cell lines with Cu(II) complexes with imidazole terpyridine, with substituted terpyridine and terpyridine ligands and some of these complexes exhibited quite low IC50 values in A549 cells. Nagababu et al. [[5]] have studied the cytotoxicity of Cu complexes, two of which also exhibited low IC50 values in A549 cell line; however, these complexes were found to be cytotoxic also toward normal cell lines. Another study reported by Feng and Liu [[58]] for A549 cells with Cu(II)-complexes based on tricationic metalloporphyrin salicyloylhydrazone ligands, however, exhibited high IC50 values.
Annexin-V FITC/PI double staining study using flow cytometry
During the initial stages of apoptosis, the cells lose their membrane phospholipid asymmetry and the membrane phospholipid phosphatidylserine (PS) is translocated from the inner face of the plasma membrane to the cell surface. PS can be easily detected by staining with fluorescent conjugated Annexin-V that specifically binds to PS exposed to the cell surface, thereby allowing the detection of early apoptotic cells. Cells are stained in parallel with propidium iodide (PI) which can enter the cells only when the plasma membrane is damaged. Therefore, viable cells are Annexin-V and PI negative (Annexin-V−, PI−). Cells undergoing early apoptosis but having intact membranes exclude propidium iodide (PI); this allows us to distinguish between early apoptotic cells (Annexin-V+, PI−) from late apoptotic cells (Annexin-V+, PI+). Necrotic cells are Annexin negative and PI positive (Annexin-V−, PI+). To see the effect of the copper complexes under study, A549 and MCF7 cells were treated with the indicated doses of 1 and 2 (1 µM, 2.5 µM, 5 µM, 10 µM, 15 µM and 20 µM) for 24 h and the percentage cell death was analyzed by Annexin-V FITC/PI staining using flow cytometry. Our results showed drastic decrease in viable cells (lower left quadrant Annexin-V−, PI−) in a dose-dependent manner upon treatment with 1 and 2 as compared to that of control cells in both A549 (Fig. 11a) and MCF7 (Fig. 11b) cell lines studied.
Graph: Fig. 11Apoptosis analysis by Annexin-V and propidium iodide staining. a A549 cells and b MCF7 cells treated with 1, 2.5, 5, 10, 15 and 20 µM of compounds 1 and 2 for 24 h. Effect on apoptosis was analyzed by Annexin-V/PI staining using flow cytometry. Representative data of three independent experiments are presented
It is observed that A549 cells upon incubation for 24 h with each of the complexes 1 and 2 show a general trend of increase in early apoptotic cells with increasing complex concentration up to 5 µM (lower right quadrant: Annexin-V+, PI−). Then a large population of late apoptotic cells 27.75% and 21.46% (upper right quadrant) corresponding to treatment of 10 µM concentration of 1 and 2 was observed. Also, it is noted that from 10 µM dose onward, there is a steady decrease in cell population in the lower right quadrant as most of the cells have passed onto the late apoptotic/necrotic stage from early apoptotic stage (Fig. 11b).
In case of MCF7 cell line upon incubation with each of the complexes 1 and 2 for 24 h, a general trend of increase in early apoptotic cells with increasing complex concentration up to 10 µM (lower right quadrant: Annexin-V+, PI−) is seen. Also a higher population of late apoptotic cells (35.05%) is observed in case of 10 µM dose of 1 (upper right quadrant) as compared to 15.19% cell population upon treatment with the same dose of 2; this observation is in good agreement with that observed in the MTT assay (Fig. 10c, d). On further increasing the complex concentration to 15 and 20 µM, there is steady decrease in the cell population in the lower right quadrant which represents early apoptotic cells, as they may have passed onto next stage (late apoptosis/necrosis) (Fig. 11b).
Cell cycle analysis
The progression of cells through the different phases of cell cycle is controlled by check points at different stages. Most of the anti-proliferative drugs target distinct points in the cell cycle and control cell cycle phase progression [[46], [59]]. Experiments were carried out to determine the phase of the cell cycle in which the compounds 1 and 2 arrested the cell growth. A549 and MCF7 cells were synchronized by serum starvation for 12 h, and after serum starvation A549 and MCF7 cells were grown in DMEM media and treated with 1, 2.5, 5 and 10 µM concentrations of 1 and 2 for 24 h. The DNA content of cells was determined by flow cytometry after the cells were stained with propidium iodide (PI). In case of both compounds, the results showed considerable increase in the G2/M phase in both cell lines in a dose-dependent manner (Fig. 12). As seen for the A549 cell line (Fig. 12a), the cell population increased up to 27.97% and 23.10% upon treatment with 10 µM dose of 1 and 2, respectively, as compared to 11.63% cell population in G2/M of control. Similarly, for MCF7 cell line, the cell population increased up to 21.05% and 23.23% upon treatment with 10 µM dose of 1 and 2, respectively, as compared, to 15.79% cell population in the G2/M of control (Fig. 12b). DNA damage is known to be a key factor that triggers cell cycle arrest. Nuclease activity studied by gel electrophoresis experiments indicate that both 1 and 2 are highly capable of inducing hydrolytic as well as oxidative DNA cleavage (Fig. 8). Thus, extensive DNA damage caused by the treatment of 1 and 2 may have resulted in the G2/M phase arrest [[45], [61]] in A549 and MCF7 cells.
Graph: Fig. 12Effects of 1 and 2 on cell cycle progression. a A549 and b MCF 7 cells treated with 1, 2.5, 5, 10, 15 and 20 µM of compounds 1 and 2 for 24 h. Effect on cell cycle arrest was analyzed by PI staining using flow cytometry. Representative data of three independent experiments are presented
Effect of compounds 1 and 2 on cellular ROS generation
To assess the capability of the complexes 1 and 2 to generate intracellular reactive oxygen species (ROS), A549 and MCF7 cells were treated with 1, 2.5, 5 and 10 µM concentrations of 1 and 2 for 24 h and the intracellular ROS levels were determined by flow cytometry using the redox-sensitive fluorescent probe 2′,7′ dichlorodihydrofluorescein diacetate (H2DCFDA). It was observed that in A549 cell line, there was considerable ROS generation upon treatment with 1 and 2. As indicated by the results at 10 µM concentration of 1 and 2, ROS detected (694.36, 705.44) was considerably high compared to untreated A549 cells (519.27) (Fig. 13a), but not so significantly high to account for the total cytotoxicity observed from their MTT assay. These observations suggest that increased ROS level may be one of the factors responsible for the observed apoptosis in A549 cells. However, in MCF7 cells we observed that 1 and 2 decreased ROS level in a dose-dependent manner and that the ROS level was drastically decreased from 1332.79 (control) to 214.29 and 223.16 upon treatment with 10 μM dose of 1 and 2, respectively (Fig. 13b), which is intriguing. There are reports that not only the increased ROS level, but also the depletion of ROS below a certain threshold level may lead to cancer cell killing [[63]]. Liou and Storz [[64]] have discussed elaborately the role of reactive oxygen species (ROS) in cancer. They have pointed out that though the role for ROS-activated Erk1/2 (extracellular regulated kinase 1/2) signaling in cell proliferation is well known [[65]–[67]], its ability to regulate cancer cell survival appears to be very specific for cell type [[68]–[70]]. As an example, they have mentioned that when MCF-7 and MDA-MB-435 breast cancer cells were treated with ROS scavengers or inhibitors that target Erk1/2 or its upstream kinase MEK (mitogen-activated protein kinase kinase), it resulted in apoptosis and cell adhesion [[71]]. Thus, the decrease in ROS levels by 1 and 2 in MCF7 cells in the present study is not surprising and may be associated with observed apoptosis. However, it is important to note that both the compounds 1 and 2 show G2/M phase cell cycle arrest in both A549 and MCF7 cell lines and activate ROS level in A549 cell line, but they act as scavengers or inhibitors of ROS in MCF7 cell line as analyzed by DCFDA staining using flow cytometry.
Graph: Fig. 13Effects of 1 and 2 on cellular ROS generation. a A549 and b MCF 7 cells treated with 1, 2.5, 5, 10, 15 and 20 µM of compounds 1 and 2 for 24 h. Effect on cellular ROS generation was analyzed by DCFDA staining using flow cytometry. Representative data of three independent experiments are presented
Conclusions
Two homodinuclear mixed ligand copper(II) complexes were structurally characterized by X-ray crystallography and their biological activities studied under identical experimental conditions. The compounds efficiently bind to CT-DNA with intercalative binding mode that is supported by viscosity measurements as well as from the fluorescence spectroscopic studies of ethidium bromide displacement assay. Both the compounds exhibit efficient hydrolytic DNA cleavage of SC pUC19 DNA and the kobs values were found to be 11.55 h−1 for 1 and 11.63 h−1 for 2, respectively. This amounts to an enormous enhancement of cleavage rate of 3.21–3.23 × 108 in comparison to the unhydrolyzed rate of ds-DNA (k = 3.6 × 10−8 h−1). Though both these compounds exhibit strong in vitro cytotoxicity against human lung cancer A549 cell line and human breast cancer MCF7 cell line as evident from significant decrease in cell viability and are found to be potent for both these cell lines as revealed from their IC50 values, compound 2, in spite of containing o-phen coligands in both the Cu(II) sites, exhibits relatively lesser cytotoxicity not only toward both the cancer cells, but also toward HaCaT normal cells as compared to compound 1 containing only one o-phen coligand in the first Cu(II) site and acetate in the second Cu(II) site. This difference may be attributed to the difference in their abilities to diffuse across the cell membrane. Annexin-V/PI dual staining results analyzed by flow cytometry strongly suggest the induction of the apoptotic pathway for the anticancer activity of these complexes. Cell cycle analysis with compounds 1 and 2 showed cell cycle arrest in the G2/M phase in both A549 and MCF7 cell lines. However, the most important observation made in this study is that compounds 1 and 2 showed differential behavior toward ROS in these two cancer cell lines. While both of them were found to be activators of ROS in A549 cells, they acted as inhibitors or scavengers of ROS in MCF7 cells.
Acknowledgements
We thank the SAIF, IIT-Madras, for XRD and SAIF, IIT-Bombay, for EPR facilities. A.P.K. thanks Mr. Atanu Banerjee and Prof. Rupam Dinda, Department of Chemistry, National Institute of Technology, Rourkela, India, for help with the ESI-MS results. MK thanks SERB, DST, Government of India, for the Project EMR/2017/001562.
Electronic supplementary material
Graph: Fig. S1. ESI–MS of the compounds 1 – 2. Fig. S2. EPR spectra of compounds 1 and 2. Fig. S3. Electronic spectra of the compounds 1 and 2. Fig. S4. Cell viability of the free Schiff base ligand and free 1,10-phenathroline ligand with human lung cancer A549 cell line after 24 h incubation time. Crystallographic data for the structural analysis have been deposited with the Cambridge Crystallographic Data Center, numbers are CCDC 1887320 for compound 1 and CCDC 1887321 for compound 2 , respectively. These data can be obtained free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html , or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: (+044) 1223-336-033; or E-mail: deposit@ccdc.cam.ac.uk (PDF 809 kb)
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
[
References
1
Santini C, Pellei M, Gandin V, Porchia M, Tisato F, Marzano C. Chem Rev. 2014; 114: 815-862. 10.1021/cr400135x
2
Barone G, Terenzi A, Lauria A, Almerico AM, Leal JM, Busto N, García B. Coord Chem Rev. 2013; 257: 2848-2862. 10.1016/j.ccr.2013.02.023
3
Todd RC, Lippard SJ. Metallomics. 2009; 1: 280-291. 10.1039/b907567d
4
Zhang CX, Lippard SJ. Curr Opin Chem Biol. 2003; 7: 481-489. 10.1016/S1367-5931(03)00081-4
5
Nagababu P, Barui AK, Thulasiram B, Shobha Devi C, Satyanarayana S, Patra CR, Sreedhar B. J Med Chem. 2015; 58: 5226-5241. 10.1021/acs.jmedchem.5b00651
6
Adak P, Ghosh B, Bauza A, Frontera A, Blake AJ, Corbella CM, Das-Mukhopadhyay C, Chattopadhyay SK. RSC Adv. 2016; 6: 86851-86861. 10.1039/C6RA14059A
7
Chauhan M, Banerjee K, Arjmand F. Inorg Chem. 2007; 46: 3072-3082. 10.1021/ic061753a
8
Vijayalakshmi R, Kanthimathi M, Parthasarathi R, Nair BU. Bioorg Med Chem. 2006; 14: 3300-3306. 10.1016/j.bmc.2005.12.049
9
Walker MG, Gonzalez V, Chekmeneva E, Thomas JA. Angew Chem Int Ed. 2012; 51: 12107-12110. 10.1002/anie.201206260
Fabbro C, Ali-Boucetta H, Ros TD, Kostarelos K, Bianco A, Prato M. Chem Commun. 2012; 48: 3911-3926. 10.1039/c2cc17995d
Farrer NJ, Salassa L, Sadler PJ (2009) Dalton Trans 10690–10701
Rajalakshmi S, Kiran MS, Nair BU. Eur J Med Chem. 2014; 80: 393-406. 10.1016/j.ejmech.2014.04.064
Rajalakshmi S, Weyhermuller T, Dinesh M, Nair BU. J Inorg Biochem. 2012; 117: 48-59. 10.1016/j.jinorgbio.2012.08.010
Basu U, Khan I, Hussain A, Kondaiah P, Chakravarty AR. Angew Chem Int Ed. 2012; 51: 2658-2661. 10.1002/anie.201108360
Basu U, Khan I, Koley D, Saha S, Kondaiah P, Chakravarty AR. J Inorg Biochem. 2012; 116: 77-87. 10.1016/j.jinorgbio.2012.06.006
Goswami TK, Gadadhar S, Roy M, Nethaji M, Karande AA, Chakravarty AR. Organometallics. 2012; 31: 3010-3021. 10.1021/om201102k
Goswami TK, Chakravarthi BVSK, Roy M, Karande AA, Chakravarty AR. Inorg Chem. 2011; 50: 8452-8464. 10.1021/ic201028e
Devereux M, Shea DO, Kellett A, McCann M, Walsh M, Egan D, Deegan C, Kedziora K, Rosair G, Muller-Bunz H. J Inorg Biochem. 2007; 101: 881-892. 10.1016/j.jinorgbio.2007.02.002
O'Connor M, Kellett A, McCann M, Rosair G, McNamara M, Howe O, Creaven BS, McClean S, Foltyn-Arfa Kia A, O'Shea D, Devereux M. J Med Chem. 2012; 55: 1957-1968. 10.1021/jm201041d
Tardio S, Basanetti I, Bignardi C, Elviri L, Tegoni M, Mucchino C, Bussolati O, Franchi-Gazzola R, Marchio L. J Am Chem Soc. 2011; 133: 6235-6242. 10.1021/ja109413c
Dey D, Kaur G, Ranjani A, Gayathri L, Chakraborty P, Adhikary J, Pasan J, Dhanasekaran D, Choudhury AR, Akbarsha MA, Kole N, Biswas B (2014) Eur J Inorg Chem 3350–3358
Festa RA, Thiele DJ. Curr Biol. 2011; 21: 877-883. 10.1016/j.cub.2011.09.040
Parveen S, Tabassum S, Arjmand F. RSC Adv. 2017; 7: 6587-6597. 10.1039/C6RA24770A
Liu J, Zhang T, Lu T, Qu L, Zhou H, Zhang Q, Ji L. J Inorg Biochem. 2002; 91: 269-276. 10.1016/S0162-0134(02)00441-5
Selvakumar B, Rajendiran V, Uma Maheswari P, Stoeckli-Evans H, Palaniandavar M. J Inorg Biochem. 2006; 100; 3: 316-330. 10.1016/j.jinorgbio.2005.11.018
Mal SK, Mitra M, Kaur G, Manikandamathavan VM, Kiran MS, Roy Choudhury A, Unni Nair B, Ghosh R. RSC Adv. 2014; 4: 61337-61342. 10.1039/C4RA09448D
Saswati Chakroborty A, Dash SP, Panda AK, Acharyya R, Biswas A, Mukhopadhyay S, Bhutia SK, Crochet A, Patil YP, Nethaji M, Dinda R. Dalton Trans. 2015; 44: 6140-6157. 10.1039/C4DT03764B
Kumaravel G, Utthra PP, Raman N. Bioorg Chem. 2018; 77: 269-279. 10.1016/j.bioorg.2018.01.024
Burstyn JN, Deal KA. Inorg Chem. 1993; 32: 3585-3586. 10.1021/ic00069a005
Deal KA, Hengge AC, Burstyn JN. J Am Chem Soc. 1996; 118: 1713-1718. 10.1021/ja952306p
Itoh T, Hisada H, Sumiya T, Hosono M, Usui Y, Fujii Y (1997) Chem Commun 677–678
Sissi C, Mancin F, Gatos M, Palumbo M, Tecilla P, Tonellato U. Inorg Chem. 2005; 44; 7: 2310-2317. 10.1021/ic049316o
Wang J, Xia Q, Zheng X, Chen H, Chao H, Mao Z, Ji L. Dalton Trans. 2010; 39: 2128-2136. 10.1039/b915392f
Lu J, Sun Q, Li JL, Jiang L, Gu W, Liu X, Tian JL, Yan SP. J Inorg Biochem. 2014; 137: 46-56. 10.1016/j.jinorgbio.2014.03.015
Li F, Xie J, Feng F. New J Chem. 2015; 39: 5654-5660. 10.1039/C4NJ02193B
Reddy PAN, Nethaji M, Chakravarty AR (2004) Eur J Inorg Chem 1440–1446
Dhar S, Reddy PAN, Chakravarty AR (2004) Dalton Trans 697–698
Ramakrishnan S, Rajendiran V, Palaniandavar M, Periasamy VS, Srinag BS, Krishnamurthy H, Akbarsha MA. Inorg Chem. 2009; 48: 1309-1322. 10.1021/ic801144x
Reddy PR, Silpa A. Polyhedron. 2011; 30: 565-572. 10.1016/j.poly.2010.11.015
Reddy PR, Silpa A. Chem Biodivers. 2011; 8: 1245-1265. 10.1002/cbdv.201000153
Koley MK, Duraipandy N, Kiran MS, Varghese B, Manoharan PT, Koley AP. Inorg Chim Acta. 2017; 466: 538-550. 10.1016/j.ica.2017.06.068
Bruker I (2016) Apex3 v2017.3-0, SAINT V8.38A, Bruker AXS Inc.: Madison (WI), USA, 2013/2014
Sheldrick GM (2014). SHELXL version 2014. University of Göttingen, Germany
Frrugia LJ. J Appl Cryst. 1997; 30: 565-566. 10.1107/S0021889897003117
Parsekar SU, Fernandes J, Banerjee A, Chouhan Om P, Biswas S, Singh M, Mishra DP, Kumar M. J Biol Inorg Chem. 2018; 23: 1331-1349. 10.1007/s00775-018-1620-2
Rastogi N, Duggal S, Singh SK, Porwal K, Srivastava VK, Maurya R, Bhatt ML, Mishra DP. Oncotarget. 2015; 6: 43310-43325. 10.18632/oncotarget.6383
Nicole JY, Marlon JH. Methods Mol Biol. 2015; 1266: 29-53. 10.1007/978-1-4939-2272-7_3
Kumar M, Parsekar SU, Duraipandy N, Kiran MS, Koley AP. Inorg Chim Acta. 2019; 484: 219-226. 10.1016/j.ica.2018.09.044
Kumar M, Parsekar SU, Duraipandy N, Kiran MS, Varghese B, Manoharan PT, Koley AP. Inorg Chim Acta. 2018; 478: 211-221. 10.1016/j.ica.2018.04.017
Anjomshoa M, Hadadzadeh H, Torkzadeh-Mahani M, Fatemi SJ, Adeli-Sardou M, Rudbari HA, Nardo VM. Eur J Med Chem. 2015; 96: 66-82. 10.1016/j.ejmech.2015.04.020
Abdi K, Hadadzadeh H, Weil M, Salimi M. Polyhedron. 2012; 31: 638-648. 10.1016/j.poly.2011.10.028
Meenongwa A, Brissos RF, Soikum C, Chaveerach P, Gamez P, Trongpaniche Y, Chaveerach U. New J Chem. 2016; 40: 5861-5876. 10.1039/C5NJ03439F
Kellett A, O'Connor M, McCann M, Howe O, Casey A, McCarron P, Kavanagh K, McNamara M, Kennedy S, May DD, Skell PS, O'Shea D, Devereux M. Med Chem Commun. 2011; 2: 579-584. 10.1039/c0md00266f
Glišic BD, Nikodinovic-Runic J, Ilic-Tomic T, Wadepohl H, Veselinovic A, Opsenica IM, Djuran MI. Polyhedron. 2018; 139: 313-322. 10.1016/j.poly.2017.11.008
Manikandamathavan VM, Nair BU. Eur J Med Chem. 2013; 68: 244-252. 10.1016/j.ejmech.2013.07.051
Rajalakshmi S, Weyhermller T, Freddy AJ, Vasanthi HR, Nair BU. Eur J Med Chem. 2011; 46: 608-617. 10.1016/j.ejmech.2010.11.041
Manikandamathavan VM, Rajapandian V, Freddy AJ, Weyhermuller T, Subramanian V, Nair BU. Eur J Med Chem. 2012; 57: 449-458. 10.1016/j.ejmech.2012.06.039
Feng X, Liu J. J Inorg Biochem. 2018; 178: 1-8. 10.1016/j.jinorgbio.2017.09.024
Senderowicz AM, Sausville EA. J Natl Cancer Inst. 2000; 92: 376-387. 10.1093/jnci/92.5.376
Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A. Can Res. 2000; 60: 566-572
DiPaola RS. Clin Cancer Res. 2002; 8: 3512-3519
Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R. Clin Cancer Res. 2002; 8: 3512-3519
Wang J, Yi J. Cancer Biol Ther. 2008; 7: 1875-1884. 10.4161/cbt.7.12.7067
Liou G-Y, Storz P. Free Radic Res. 2010; 44: 479-496. 10.3109/10715761003667554
Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. Science. 1997; 275: 1649-1652. 10.1126/science.275.5306.1649
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Biochim Biophys Acta. 2007; 1773: 1263-1284. 10.1016/j.bbamcr.2006.10.001
Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Cancer Res. 2008; 68: 1777-1785. 10.1158/0008-5472.CAN-07-5259
Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK, Ngan HY. Carcinogenesis. 2008; 29: 1742-1750. 10.1093/carcin/bgn167
Lee WC, Choi CH, Cha SH, Oh HL, Kim- YK. Neurochem Res. 2005; 30: 263-270. 10.1007/s11064-005-2449-y
Rygiel TP, Mertens AE, Strumane K, van der Kammen R, Collard JG. J Cell Sci. 2008; 121: 1183-1192. 10.1242/jcs.017194
Ostrakhovitch EA, Cherian MG. J Cell Biochem. 2005; 95: 1120-1134. 10.1002/jcb.20484
Zhou J, Chen Y, Lang J-Y, Lu J-J, Ding J. Mol Cancer Res. 2008; 6: 194-204. 10.1158/1541-7786.MCR-07-0197
]
By Sidhali U. Parsekar; Manohar Singh; Durga P. Mishra; P. K. Sudhadevi Antharjanam; Aditya P. Koley and Manjuri Kumar
Reported by Author; Author; Author; Author; Author; Author